LeonaBio Q1 2026 net loss $32.9M ($1.73/share); cash burn $20.9M; ELAINE-3 enrollment target Q4 2026

LeonaBio, Inc.

2026-Q1 EPS reported -$1.73

Net loss of $32.9M ($1.73 per share) vs $9.1M ($2.34) in Q1 2025, driven by higher R&D spend.
Cash, equivalents and investments $67.7M at March 31, 2026, down from $88.3M at Dec 31, 2025.
R&D expenses $10.3M (up 139% YoY) due to Phase 3 ELAINE-3 lasofoxifene trial costs.
Expects to complete enrollment of Phase 3 ELAINE-3 in Q4 2026; topline data 2H 2027.
Appointed Fred Callori, Natalie Holles, Peter Silverman to Board; John Fluke Jr. retired.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LeonaBio, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, LeonaBio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-211867

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.